Articles tagged with Molecular Targets
Revolver Therapeutics, a spin-out company from the University of Bath, has won the Health category of the Royal Society of Chemistry's Emerging Technologies Competition with its proprietary discovery platform. The platform generates and tests millions of constrained peptide drug candidates directly inside living cells, selecting for mo...
Researchers at the University of Houston have discovered adding salt can help release therapeutic material from endosomes, improving delivery efficiency for mRNA vaccines and gene therapies. The simple strategy overcomes a major obstacle in gene medicine, potentially making these therapies more efficient and accessible worldwide.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
A team of scientists has uncovered more than 1,700 new proteins known as peptideins, which are smaller than traditional proteins and may have unique biology. These proteins were found in the 'dark proteome', a section of DNA previously overlooked, and could have implications for human diseases like cancer.
A team of researchers has uncovered a promising new target for antimalarial drug design, identifying an enzyme called aminopeptidase P from the Plasmodium falciparum parasite. The new inhibitors have been shown to bind more strongly and selectively than existing compounds, demonstrating potential as a new class of drugs to combat malaria.
Researchers have discovered a biomarker for chemotherapy resistance in small cell lung cancer, which can help identify cells that become more invasive and lead to treatment resistance. Targeting these cells with YAP1 may be a possible strategy to improve patient outcomes.
A research consortium has developed mini-antibodies that can reactivate mutated p53, a key tumor suppressor protein. These DARPins bind selectively to p53 mutants, restoring stability and functionality, making them potentially useful against various types of tumors.
Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.
The VCU Massey Comprehensive Cancer Center has completed the inaugural funding cycle of its collaborative drug discovery program with the Sanford Burnham Prebys Medical Discovery Institute. Two projects have received $50,000 each to advance innovative cancer drug discovery efforts.
Scientists have discovered genetic pathways and compounds that protect cone photoreceptors, crucial for central vision, from degeneration associated with age-related macular degeneration. The study used human retinal organoids and identified two kinase inhibitors as key protective mechanisms.
The collaboration aims to identify therapeutic targets for challenging gynecological conditions using Insilico's AI-driven target identification engine, PandaOmics. ASKA will validate the AI-predicted targets with high translational potential, accelerating the development of innovative solutions for millions of patients worldwide.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Researchers at Goethe University are developing non-hormonal contraceptives to address declining pill use and side effects. The PREVENT project aims to create safe and effective alternatives, focusing on small molecules that block proteins in sperm or egg cells.
ISM4808, a PHD inhibitor for chronic kidney disease-related anemia, has achieved its first milestone with successful completion of the Phase I clinical trial. The treatment stimulates endogenous erythropoietin production and improves iron utilization, offering improved efficiency and safety compared to existing treatments.
A study from The University of Osaka reveals a molecular pathway connecting liver congestion to liver fibrosis, portal hypertension, and liver tumorigenesis. Researchers identified increased activity of YAP and CTGF in liver sinusoidal endothelial cells as key molecules involved in this signaling pathway.
Insilico Medicine nominates ISM5059, a peripheral-restricted NLRP3 inhibitor, as a preclinical candidate for treating various inflammatory diseases. The compound has demonstrated high potency, selectivity, and excellent in vivo efficacy across animal disease models.
The collaboration aims to accelerate the development of small molecule inhibitors for treating metabolic diseases. Insilico will utilize its Pharma.AI platform to design and optimize novel molecules, while Qilu will handle subsequent development and commercialization.
The article highlights Insilico Medicine's exclusive contributions to two chapters in the latest AI for Drug Discovery Volume, showcasing its expertise in real-life application of AI in early drug target-related tasks. The company's roadmap to 2030 using Quantum Machine Learning (QML) algorithms is also presented, with successful case ...
The companies will jointly develop ISM8969, a brain penetrant NLRP3 inhibitor for treating neuroinflammation-related diseases. Preclinical data shows the molecule's efficacy and favorable safety profile.
Insilico Medicine's Phase IIa clinical trial assesses Garutadustat's safety and efficacy in ulcerative colitis. The novel PHD inhibitor has shown favorable safety and tolerability profiles in completed Phase I studies.
Insilico Medicine collaborates with Servier to develop novel therapeutics in oncology through AI-driven platform Pharma.AI. The partnership is focused on identifying promising targets and generating molecular structures with desired properties.
Insilico Medicine raised a total of HKD 2.277 billion in its largest Hong Kong biotech IPO, with 94,690,500 shares offered globally and oversubscribed by approximately 1427 times. The company aims to advance its mission of extending human productive longevity using AI-powered drug discovery and development.
Researchers at Harvard Medical School have uncovered crucial insights into how a new class of antiviral drugs works, shedding light on an important tool for fighting drug-resistant strains of herpes simplex virus. The discovery may lead to new pathways for treating herpesviruses and other kinds of DNA viruses.
Researchers developed a new imaging technique called vCATCH to map drug binding in individual cells throughout the entire mouse body. The method revealed unexpected binding sites for two cancer drugs, providing clues about their side effects.
Scientists have discovered a shape-shifting molecular valve in PANX1, a cellular gate that controls the flow of chemical messages. Researchers found that a common antimalarial drug can enhance or inhibit this gate's activity, paving the way for precision therapies.
Insilico Medicine and Taigen Biotechnology collaborate to develop and commercialize ISM4808, an AI-driven PHD inhibitor for treating anemia of Chronic Kidney Disease (CKD). The partnership grants TaiGen exclusive rights for further development, commercialization, and sub-licensing in the Greater China area.
Insilico Medicine's Chemistry42 platform enables the efficient discovery of a potent, oral CBLB inhibitor with low toxicity risks and favorable ADME/PK profiles. The compound demonstrates strong in vitro activity and improved metabolic stability in mouse, rat, and dog models.
Insilico Medicine has nominated ISM3830, a highly selective CBLB inhibitor, as a preclinical candidate for advanced tumor immunotherapy. ISM3830 showed robust anti-tumor activity in multiple murine models and induction of long-term tumor immunity.
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
The collaboration combines Insilico's Pharma.AI platforms with Lilly's expertise to discover and advance new therapies. Insilico will utilize its platform to generate candidate compounds, accelerating the development of transformative treatments for urgent patient needs.
Researchers focus on unraveling immunoregulatory mechanisms in sepsis, exploring the NF-κB and JAK/STAT signaling pathways. Emerging treatments aim to mitigate hyperinflammation and prevent organ failure through personalized, multi-target modulatory approaches.
UCSF researchers found a key cellular switch driving pulmonary fibrosis and developed a new therapy to block it in mice. The treatment works by preventing healthy lung cells from converting to harmful cell types, reducing scarring and improving lung function.
Researchers at the University of Bath develop a peptide fragment that locks alpha-synuclein into its healthy shape, blocking toxic clumps that cause nerve cell death. The breakthrough demonstrates the potential of rational peptide design to transform large proteins into compact drug-like molecules.
Pharma.AI is a comprehensive generative AI-powered drug discovery platform featuring PandaOmics, Generative Biologics, Chemistry42, Science42: DORA, and PreciousGPT. These platforms enhance target and biomarker discovery, biologics engineering, small molecule design, scientific research, and disease modelling.
Researchers created a glycan-binding protein that can analyze and treat diseases via sugar patterns found on the surface of cells. The tool, named sCore2, was developed by retraining an enzyme to bind to specific sugars, providing a new way to study glycans and their role in disease.
Insilico Medicine has completed IND-enabling studies for ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders. The drug candidate demonstrated favorable PD/PK profiles and dose-dependent efficacy in motor functions in animal models.
A Korean research team has developed a new single-atom catalyst that selectively performs only peroxidase-like reactions while maintaining high reaction efficiency. The platform enables test results to be read within minutes in near-physiological conditions, improving medical accessibility and ensuring timely treatment.
The Insilico Medicine recent summer updates webinar introduced new features and functional updates to the company's generative AI platform, including Generative Biologics, Chemistry42, PandaOmics, DORA, and PreciousGPT. These updates aim to accelerate drug discovery and advance life sciences research.
Insilico Medicine's latest Pharma.ai updates showcase advancements in Biology42 and Chemistry42, enhancing antibody design and omics data analysis. The company's AI software suite has demonstrated significant efficiency improvements in practical applications, setting a benchmark for AI-driven drug research.
At the upcoming AI for Good Global Summit, Alex Zhavoronkov PhD will discuss the future potential of generative AI. Insilico Medicine's founder and CEO has invented critical technologies in generative AI and reinforcement learning, and his keynote will explore applications in drug discovery and longevity.
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
Insilico Medicine has completed the first-in-patient dosing of ISM3412, a novel MAT2A inhibitor with potential as a best-in-class treatment for locally advanced and metastatic solid tumors. The Phase 1 study aims to evaluate safety, tolerability, and preliminary anti-tumor efficacy of ISM3412.
Researchers at EPFL have created ultra-selective aptamers that target specific binding sites on viral spike proteins with unprecedented precision. These multivalent binders show stronger and more selective binding affinities than traditional monovalent binders, making them promising for biomedical diagnostics and therapeutics.
The Phase IIa trial of Rentosertib showed encouraging clinical data, with patients receiving the treatment experiencing significant improvements in lung function compared to placebo. The study also validated the biological mechanism of TNIK inhibition using exploratory biomarkers analyses.
The Psychedelics journal has expanded its focus to include all psychoactive drugs, challenging traditional classifications and embracing a broader understanding of consciousness-altering substances. This move aims to reveal novel therapeutic applications and deepen human knowledge of the mind.
Researchers developed a carbene-catalyzed phthalide ether functionalization method, creating chiral phytovirucides targeting the viral Nia protein. The compounds showed superior antiviral efficacy against Potato virus Y (PVY), with potential for developing new plant viruses management strategies.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A new study finds that radioiodine therapy significantly increases relative survival rates in differentiated thyroid cancer patients, with benefits observed across low-, intermediate-, and high-risk subgroups. The treatment reduces recurrence rates and improves long-term survival in high-risk groups, while also showing promise for low-...
A research team developed a novel strategy to balance high catalytic activity and durability under industrial-level conditions. They constructed a MOF@POM superstructure that undergoes an in-situ transformation into a single-layer CoFe hydroxide catalyst, exhibiting exceptional performance in alkaline electrolytes.
Long non-coding RNAs (lncRNAs) play a crucial role in regulating the tumor microenvironment, influencing processes such as immune evasion, angiogenesis, and metastasis. They mediate interactions between tumor cells and their surrounding microenvironment, modulating stromal cell activities and promoting tumor growth and survival.
A recent study discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and mouse models. This approach shows promise for treating pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, which is challenging to treat due to its cellular environment.
A new study at Stellenbosch University found that blocking the enzymes involved in glycolysis could cut off the malaria parasite's primary energy source and kill it. This approach has shown promise for developing new malaria drugs, particularly against resistant parasites.
A research team at the California NanoSystems Institute has created the most detailed 3D map yet of the flagellum on Trypanosoma brucei, which causes sleeping sickness. The study identified 154 different proteins that make up the flagellum, including 40 unique to the parasite.
Researchers at UCSF's AViDD Center have developed powerful drug candidates that outperformed Paxlovid in preclinical testing against SARS-CoV-2 and MERS. The compounds could inhibit coronaviruses in general, providing a head start against future pandemics.
Researchers have discovered a new druggable cancer target, NPM1, which is expressed on the surface of malignant AML cells. Monoclonal antibodies targeting NPM1 showed robust anti-tumor activity in multiple in vivo models of AML, with no apparent toxicity to non-cancerous blood cells and stem cells.
Bacteria use tactile sensors to detect surfaces and trigger biochemical signals for colonization. Understanding mechanosensing is crucial for improving gut health and preventing biofouling in industries.
Researchers at UT Arlington's CIHI are developing innovative solutions to address complex health needs in children with disabilities, behavioral health issues, and medical conditions. The projects aim to improve healthcare services, enhance quality of life, and promote healthier aging through cutting-edge research and model organisms.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.